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The severity of Pseudomonas aeruginosa (PA) infection may be determined by the interaction with the host
immune system. We designed a prospective study to assess the relationship between the inflammatory response
and the clinical presentation and outcome of PA infection. We also investigated whether there are differences in
the inflammatory response depending on the resistance profile of PA. Interleukin-6 (IL-6), IL-10, procalcitonin
(PCT), and C-reactive protein (CRP) were measured. Sixty-nine infection episodes were recorded; 40 caused by
non-multidrug-resistant (non-MDR) strains [29 (73%) respiratory; 8 (20%) bacteremia], 12 by MDR non-
extensively drug-resistant (MDR-non-XDR) [9 (75%) respiratory; 3 (25%) bacteremia], and 17 by XDR strains
[9 (53%) respiratory; 7 (41%) bacteremia]. All inflammatory parameters were significantly higher in patients
who developed acute organ dysfunction and bacteremia. PCT levels were higher in patients with early mortality
[p = 0.050]. Inflammatory biomarkers were higher in patients with XDR than in those with non-MDR PA [IL-6
430 (67–951) vs. 77 (34–216), p = 0.02; IL-10 3.3 (1.5–16.3) vs. 1.3 (0–3.9), p = 0.02; and PCT 1.1 (0.6–5.2) vs.
0.3 (0.1–1.0), p = 0.008]. The intensity of inflammatory response was associated with the severity of PA
infection, particularly if bacteremia occurred. Only PCT was documented useful to predict the outcome. XDR
infections presented a higher inflammatory response; related in part to the larger number of bloodstream
infections in this group.
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Introduction
Pseudomonas aeruginosa (PA) is a common and se-rious cause of nosocomial infections. Mortality due to
PA bacteremia may be as high as 50% within the first
24–72 hr.1,2 Poor outcomes in PA infections have been as-
sociated with factors related to the antibiotic treatment, mi-
croorganism, and host. The presence of multidrug-resistant
(MDR) strains reduces treatment options and raises the risk
of receiving an inadequate initial antimicrobial treatment.
Nonetheless, previous studies by our group found that early
mortality was higher in non-MDR than MDR PA infections,
suggesting that non-MDR PA infections have a more virulent
behavior.1–3 It is known that the severity of acute illness
presentation is associated with a higher mortality,4,5 and
probably differences in the presentation of acute illness is
determined not only by the production of PA virulence fac-
tors, but also by the interaction between the bacteria and the
host innate immune system.
The early phase of sepsis is dominated by a hyperin-
flammatory state mediated by a systemic production of cyto-
kines, as interleukin 6 (IL-6), which are required for adequate
host defense against infection. Occurring almost simulta-
neously, the production of anti-inflammatory cytokines (IL-10),
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reduces local and systemic toxicity, and serves to balance the
inflammatory state. However, an excessive inflammatory re-
sponse may progress to sepsis and, ultimately, multiple organ
dysfunction syndrome; on the other hand, an excessive anti-
inflammatory response may hamper the resolution of the in-
fection.6,7 Several researchers have shown that the levels of
both pro- and anti-inflammatory cytokines may be correlated
with illness severity and that unbalanced inflammatory re-
sponse is a strong predictor of mortality.8–10 In addition, other
biomarkers of inflammation have been widely used as clinical
markers of bacterial infections. C-reactive protein (CRP) is an
acute-phase reactant synthesized by the liver during the in-
flammation with both proinflammatory and anti-inflammatory
effects.11 More recently, Procalcitonin (PCT), the prohormone
of calcitonin, has demonstrated to be an useful marker for the
diagnosis of sepsis. Among its advantages, PCT shows a fa-
vorable kinetic profile in sepsis, as appears in plasma earlier and
longer than CRP or cytokines. Moreover, PCT levels correlate
with the severity of the infection.11,12 Despite its usefulness, the
biological role of PCT in sepsis is still unknown.11
To date, several studies in severe pneumonia13–15 and in
sepsis16,17 have evaluated the inflammatory response; how-
ever, data regarding the inflammatory response in acute PA
infections are limited18,19 and in fact the issue has not been
examined in humans. Nor has the possible correlation of
multidrug resistance with the ability of the pathogens to elicit
immune response been assessed.18
We designed a prospective study of PA infections in an
ICU unit to assess the profile of the inflammatory response
in PA infection. We measured several molecular inflam-
matory markers at two serial time points to: (i) determine
the sequential changes in the expression of proinflammatory
and anti-inflammatory cytokines and other markers of in-
flammation (PCT and CRP) in blood, during the first 48 hr
after the onset of PA infection, (ii) analyze the relationship
between these markers and the severity of the presentation
of the acute illness and outcome, and (iii) establish whether
there are differences in the molecular inflammatory re-




This prospective cohort study was performed at one of the
three general ICUs at the Hospital Universitari de Bellvitge,
a 700-bed tertiary-care institution for adult patients in Bar-
celona. The ICU is a 12-bed, private room ward providing
care to medical and surgical patients, including those who
have undergone solid organ transplantation. The study in-
cluded all patients admitted to the ICU for more than 48 hr
during an 18-month period (1 January, 2012 to 1 July,
2013). An active surveillance study was performed as pre-
viously reported.20 Patients were prospectively monitored
from ICU admission to ICU discharge, through daily clinical
evaluation to detect whether they presented any sign of in-
fection. In addition, a daily review of microbiological cul-
tures was performed. When any patient presented clinical
parameters of infection, clinical and blood sample were
collected for the microbiological diagnostic and to analyze
inflammatory biomarkers, respectively. Despite the pro-
spective design of the study, the differentiation between
infection and colonization is often difficult in critically ill
patients. For this reason, we excluded nonbacteriemic uri-
nary tract infections from the study, in addition to skin and
soft tissue infections. Only evident acute infections with
clinical significance were included: respiratory tract infec-
tions, bacteremia, or other infections in which the clinical
sample has been obtained by surgery or sterile puncture
(e.g., intra-abdominal). All patients with PA infection were
recruited in the study prospectively. Patients with any of the
following criteria were excluded: length of ICU stay lower
than 48 hr, polymicrobial infection; patients with other
concomitant infection; and patients with do-not-resuscitate
orders. The local Ethics Committee of our hospital approved
the study, and patients or family provided informed consent.
Definitions
The following data were recorded: age and sex; co-
morbidities and severity of underlying diseases calculated
using the Charlson comorbidity index21 and severity of illness
estimated by the Simplified Acute Physiology Score (SAPS II)
in patients at ICU admission and at the onset of infection.22
Additionally, to analyze data according to the immune status,
we created the variable ‘‘immunocompromised,’’ which in-
cluded solid or hematologic malignancy, neutropenia, or pa-
tients under immunosuppressant treatment. The onset of PA
infection was defined as the day in which the patient presented
any sign of infection and clinical samples were collected for
the microbiological diagnostic. In patients with multiple epi-
sode of infection, a second episode was defined when a new
infection occurred at least 72 hr after the clinical resolution of
the preceding episode. The source of infection was established
according to the Centers for Disease Control and Prevention
Criteria23; in addition, ventilator-associated tracheobronchitis
and ventilator-associated pneumonia were classified accord-
ing to the clinical pulmonary infection score,24 and the se-
verity of acute bacteremic illness at presentation and 48 hr
according to the Pitt bacteremia score.25 Acute inflammatory
response was classified as sepsis, severe sepsis, septic shock,
and multiorgan dysfunction syndrome (MODS) according to
consensus definitions.26 We also used the sepsis-related organ
failure assessment (SOFA) score and defined acute organ
dysfunction as the dysfunction of three or more organs in any
of six organ systems.27 For outcomes, overall mortality was
defined as death from any cause occurring in the 30 days after
the onset of PA infection; mortality was considered as early in
patients who died within the first 5 days.
The phenotype stratification of PA isolates was made in
accordance with recent standard definitions.28 MDR PA was
defined as a strain nonsusceptible to ‡1 agent in ‡3 anti-
pseudomonal antimicrobial categories. Extensively drug-
resistant (XDR) PA was defined as nonsusceptible to ‡1
agent in all but £2 antipseudomonal antimicrobial cate-
gories; thus, XDR PA isolates were included as MDR PA.
To study the specific epidemiology of XDR PA, MDR PA
isolates were distributed as follows: XDR PA as defined
above, and MDR-non-XDR PA defined as PA strains non-
susceptible to ‡1 agent in ‡3 antipseudomonal antimicrobial
categories, but susceptible to at least >2 antipseudomonal
antimicrobial classes. All other PA isolates, including those
nonsusceptible to ‡1 agent in <3 antimicrobial categories,
were considered non-MDR PA.
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Collection of blood samples and laboratory processing
For all PA-infected patients, two serial blood samples
were obtained at infection onset and 48 hr later. We mea-
sured circulating levels of IL-6 as marker of the proin-
flammatory cytokine response and IL-10 as a marker of the
anti-inflammatory cytokine response; PCT and CRP bio-
markers were also analyzed. The blood obtained was placed
in tubes containing EDTA, immediately centrifuged, and
stored at -80C. Cytokines were measured by flow cytometry
using the cytometric bead arrays technology. Samples were
analyzed using a BD FACSCalibur flow cytometer (BD
Biosciences), according to manufacturer’s instructions. Sam-
ples were analyzed in duplicate. The detection limit was 5 pg/
ml for IL-6 and 1 pg/ml for IL-10. PCT levels were measured
by electrochemiluminescence immunoassay using the Modular
Analytics e170 immunoassay analyzer (Roche Diagnostics),
with a detection limit of 0.02 ng/ml. CRP levels were measured
using an immunoturbidimetric assay in a Cobas c711 analyzer
(Roche Diagnostics), with a detection limit of 1 mg/L.
Microbiological studies
The isolates were identified and tested for antimicrobial
susceptibility by a MicroScan automated microdilution
system using CN1S and CO1S panels (Dade International,
West Sacramento, CA). The following antimicrobial agents
were tested: aztreonam, ceftazidime, cefepime, piperacillin,
piperacillin-tazobactam, imipenem, meropenem, gentami-
cin, tobramycin, amikacin, levofloxacin, ciprofloxacin, co-
listin, and fosfomycin. Clinical categories were determined
according to the CLSI breakpoints.
Statistical analysis
Quantitative variables were expressed as the mean – SD,
medians and interquartile range (IQR). The variables were
compared by the two-tailed t-test or Mann–Whitney U-test.
The chi-square test or Fisher’s exact test were used to com-
pare categorical variables. Variables with a p < 0.05 were
considered statistically significant. Cytokine measurements
in the different PA phenotypes were compared with non-
parametric test (Mann–Whitney U-test or Kruskal–Wallis
test). A stratified analysis based on the type of infection (i.e.,
respiratory tract infection and bacteremia) was performed. In
addition, as an immunosuppression status may modulate the
immune response during the infection, we also carried out
a stratified analysis according to the immune status of the
patient. Data were analyzed using SPSS version 19.0.
Results
Baseline characteristics of the included population
The epidemiological characteristics of the patients with
PA infection are summarized in Table 1. Sixty-nine epi-
sodes of infection were recorded in the 61 patients included.
Six patients presented a second episode of infection: five
with the same strain isolated in the first episode (two non-
MDR and three XDR PA) and one patient with initial MDR
non-XDR infection presented a second episode by non-MDR
strain. Only one patient had a third episode of infection,
caused by the same XDR PA strain. Forty-eight episodes
were respiratory tract infections (three of them with bacter-
emia) and 18 bloodstream infections. Among the remaining
six episodes, three episodes were intra-abdominal infections
Table 1. Baseline Characteristics of Patients with Pseudomonas aeruginosa
Infection According to Phenotype
Characteristic
Non-MDR PA MDR non-XDR PA
pa
XDR PA
pbn = 37 (%) n = 11 (%) n = 13 (%)
Age (mean – SD) 67.2 – 12.3 58.9 – 11.8 0.06 67.3 – 17.2 0.98
Male sex 25 (67.6) 9 (81.8) 0.27 9 (69.2) 0.92
Days ICU-infection acquisition [median (IQT)] 14.5 (3.75–31) 14.5 (8.75–35.75) 0.63 8.5 (3.5–15.0) 0.21
SAPS score mean (SD) 42.0 – 17.2 41.4 – 13.0 0.91 44.3 – 9.2 0.66
Charlson index [median (IQT)]) 1 (0.75–4) 3 (2–4) 0.18 2 (1.25–4) 0.39
Underlying condition
Diabetes 7 (19) 1 (10) 0.65 1 (8) 0.66
Chronic lung disease 3 (8) 3 (30) 0.12 3 (23) 0.17
Heart Disease 13 (35) 2 (20) 0.45 5 (38) 0.83
Solid malignancy 6 (16) 3 (30) 0.40 3 (23) 0.67
Hematologic malignancy 1 (3) 1 (10) 0.40 0 —
Chronic renal failure 3 (8) 2 (20) 0.31 1 (8) 0.95
Chronic neurologic disease 3 (8) 3 (30) 0.12 1 (8) 0.72
Cirrhosis 2 (5) 3 (30) 0.07 3 (23) 0.06
Neutropenia 0 0 — 0 —
Immunosuppression 10 (27) 1 (10) 0.40 2 (15) 0.47
Outcome
Early exitus 6 (16) 1 (10) 0.56 1 (8) 0.40
Overall exitus 7 (19) 1 (10) 0.65 2 (15) 0.56
Days ICU-discharge/exitus [median (IQT)] 53 (26.5–87.25) 59.5 (39.25–86.25) 0.50 68.5 (21.0–87.75) 0.72
aComparison of non-MDR and MDR non-XDR.
bComparison non-MDR and XDR.
SD, standard deviation; PA, P. aeruginosa; MDR, multidrug-resistant; XDR, extensively drug-resistant; ICU, intensive care unit; IQT,
interquartile range; MODS, multiorgan dysfunction syndrome.
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that required emergency surgery, two episodes were central
nervous system infections and one episode was a mediasti-
nitis. A stratified analysis according to the inmmune status of
patients, which could account for a different immune re-
sponse, did not show significant differences as compared with
the overall analysis (data not shown). Higher early mortality
was observed in patients with non-MDR PA infections versus
MDR PA infections, though the difference was not statisti-
cally significant (16% for non-MDR vs. 10% for MDR non-
XDR and vs. 8% for XDR PA).
Molecular inflammatory response and severity
of acute illness
Cytokine and biomarkers concentrations at presenta-
tion. Blood was obtained for assay of cytokine concentra-
tions and markers of inflammation at presentation from 69
infections of the 61 subjects. IL-6, CRP, and PCT levels
were detected in all infection episodes analyzed. However,
27.5% (19/69) of IL-10 samples had undetected concentra-
tions. The medians of IL-6 and IL-10 were higher in XDR
Table 2. Episodes of P. aeruginosa Infection: Clinical and Molecular Inflammatory Response
Characteristic
Non-MDR PA MDR non-XDR PA
pa
XDR PA
pbn = 40 (%) n = 12 (%) n = 17 (%)
Origin of infection
High risk origin 38 (95) 10 (83) 0.22 14 (82) 0.12
Unknown 3 0 1
Respiratory tract 29 10 9
Abdominal 3 0 3
Other(s) 3 0 1 -
Low risk origin 2 (5) 2 (17) 0.22 3 (18) 0.12
Vascular catheter 1 2 2
Urinary tract 0 0 1
Pancreaticobiliary 1 0 0
SAPS score [mean (SD)] at infection 47.1 – 14.8 44.6 – 12.7 0.60 56.5 – 17.6 0.04
Bacteremia 8 (20) 3 (25) 0.70 7 (41) 0.09
Initial presentation
Pitt score [median (IQT)] 3 (2–5.50) 1 (0–1) 0.15 6 (6–6) 0.22
IL-6 [median (IQT)] 360 (44–945) 93 (64–93) 0.50 183 (53–789) 0.78
IL-10 [median (IQT)] 11.7 (0.2–22.7) 13.5 (3.8–13.4) 1.00 11.8 (2.76–19.6) 1.00
Procalcitonin [median (IQT)] 3.75 (1.45–11.1) 0.77 (0.50–0.77) 0.085 2.99 (1.16–18.63) 0.96
CRP [median (IQT)] 241 (67–361) 34 (21–337) 0.194 191 (87–394) 0.95
Sepsis (any severity) 7 (87.5) 2 (66.7) 0.491 6 (85.7) 0.73
48 after bacteremia
Pitt score [median (IQT)] 0 (0–5.25) 0 — 3.5 (1.5–4.0) 0.91
IL-6 [median (IQT)] 52 (25–167) 60 (22–170) 0.63 36 (25–138) 0.66
IL-10 [median (IQT)] 1.15 (0.2–11.9) 7.7 (3.3–12.9) 0.19 7.21(0.5–13.2) 1.00
Procalcitonin [median (IQT)] 2.42 (1.2–9.3) 0.83 (0.4–0.9) 0.50 1.39 (0.52–5.81) 0.96
CRP [median (IQT)] 174 (79–298) 43 (17–198) 0.78 84 (51–303) 0.62
Sepsis (any severity) 4 (50) 1 (33) 0.58 5 (83.3) 0.24
Initial clinical presentation
Sepsis 6 (15) 4 (33) 0.21 0 -
Severe sepsis 8 (20) 1 (8) 0.66 2 (12) 0.70
Shock 9 (22.5) 2 (17) 0.50 11 (65) 0.002
MODS 3 (7.5) 0 — 4 (23.5) 0.18
Initial molecular inflammatory response
IL-6 [median (IQT)] 77 (34–216) 38 (24–86) 0.15 430 (67–951) 0.02
IL-10 [median (IQT)] 1.3 (0–3.9) 2.7 (0–11.8) 0.41 3.3 (1.5–16.3) 0.02
Procalcitonin [median (IQT)] 0.3 (0.1–1.0) 0.3 (0.1–2.4) 0.70 1.1 (0.6–5.2) 0.008
CRP [median (IQT)] 191 (79–305) 103 (41–184) 0.12 202 (56–332) 0.83
Clinical presentation at 48 hr
Sepsis 2 (5) 0 — 4 (25) 0.05
Severe sepsis 5 (13) 1 (8) 0.56 6 (37.5) 0.03
Shock 6 (15) 1 (8) 0.47 2 (12.5) 0.57
MODS 2 (5) 1 (8) 0.56 0 —
Molecular inflammatory response at 48 hr
IL-6 [median (IQT)] 58 (30–104) 19 (15–49) 0.02 86 (31–324) 0.33
IL-10 [median (IQT)] 1.7 (0–7.5) 0.98 (0–6.6) 0.60 2.9 (0.7–7.8) 0.52
Procalcitonin [median (IQT)] 0.2 (0.1–17) 0.3 (0.1–1.1) 0.96 0.9 (0.5–4.1) 0.03
CRP [median (IQT)] 96 (47–256) 44 (28–105) 0.14 124 (41–299) 0.58
aComparison non-MDR and MDR non-XDR.
bComparison non-MDR and XDR.
IL, interleukin; CRP, C-reactive protein.
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PA infections than in non-MDR PA infections ( p = 0.02). In
addition, the PCT level was also significantly higher in XDR
PA infections ( p = 0.008) (Table 2). We also observed a
significant number of episodes subsequently developing
septic shock ( p = 0.002) in XDR PA infections than in non-
MDR PA infections. A trend toward higher MODS in XDR
PA versus non-MDR PA infections was found, although the
differences were not statistically significant ( p = 0.18). The
analysis of the molecular and clinical inflammatory response
in bacteremic group is shown in Table 2. No significant
differences in the progression to sepsis were observed be-
tween PA phenotypes. However, non-MDR and XDR PA
strains presented a higher number of bacteriemic sepsis
patients than MDR non-XDR strains, as it is shown in
Table 2. Regarding respiratory tract infections, the median
levels of IL-6 were higher in non-MDR PA than in MDR
non-XDR PA episodes, with a difference close to statistical
significance [69 (36–126) vs. 36 (23–57); p = 0.06]. The
level of PCT was significantly higher in XDR PA than in
non-MDR PA [0.92 (0.24–1.80) vs. 0.24 (0.12–0.52);
p = 0.05]. No other statistically significant differences were
observed at the onset of the infection in the respiratory in-
fection group.
Cytokine and biomarkers concentrations 48 hr after infec-
tion onset. We obtained blood for assay of concentrations of
cytokine and inflammation markers 48 hr after presentation
from 67 infections (Table 2). Concentrations of IL-10 were
undetected in 26% (18/67) of samples; the other markers of
inflammation were detected in all samples. The median level
of IL-6 was higher in non-MDR infections than in MDR
non-XDR infections ( p = 0.02), and the level of PCT at 48 hr
remained significantly higher in XDR PA infections than in
non-MDR PA infections ( p = 0.03). Data regarding the
molecular inflammatory response at 48 hr of the infection in
bacteriemic group are shown in Table 2. Regarding to re-
spiratory infection group, we observed that IL-6 levels re-
mained higher in non-MDR than in MDR non-XDR PA
after 48 hr [65 (32–104) vs. 17 (15–30); p = 0.001]. No other
significance differences were observed at 48 hr in this group
when comparing the biomarkers levels according to PA
phenotypes.
Molecular inflammatory response in acute organ
dysfunction and in bacteremic infections
Concentrations of cytokines and other inflammatory
markers are presented in Table 3, according to the definition
of acute organ dysfunction using the SOFA score. Medians
of all parameters were significantly higher in patients who
developed acute organ dysfunction at infection onset. These
differences between the groups remained significant 48 hr
after infection onset, except in the case of IL-10; IL-10
levels remained high at 48 hr but the differences were not
significant. We also observed significant differences in the
levels of IL-6, IL-10, and PCT at onset between bacteremic
and nonbacteremic infections. However, after 48 hr, only
PCT levels still presented significant differences (Table 4).
Molecular inflammatory response and outcome
In general, plasma cytokine concentrations were higher in
nonsurvivors than survivors; however, these differences did
not reach statistical significance in either early mortality
(those who died within 5 days) or overall mortality (Table 5).
Only PCT levels presented significant differences [median,
IQT: 0.4 (0.1–1.6) between survivors and 2 (0.4–5.7) in
nonsurvivors; p = 0.050] at infection onset. None of the ana-
lyzed parameters—cytokines, PCT or CRP -, either at base-
line or after 48 hr were related to higher overall mortality
(Table 5).
Discussion
The aim of this study was to analyze the profiles of cy-
tokines and other biomarkers in blood of ICU patients with
Table 3. Inflammatory Response According to Acute Organ Dysfunction






(n = 58) p (n = 18)
No organ
dysfunction
(n = 49) Organ dysfunction p
IL-6 [median (IQT)] 20 (10.8–52.8) 104 (42.1–435.4) <0.001 28.1 (12.4–49) 66 (32.1–161.6) <0.001
IL-10 [median (IQT)] 0.2 (0–1.7) 2.5 (0.06–9) 0.03 1.5 (0–4.2) 2.4 (0–8.3) 0.72
Procalcitonin [median (IQT)] 0.1 (0.06–0.8) 0.5 (0.2–3.2) 0.01 0.3 (0.1–0.7) 0.5 (0.1–1.8) 0.02
CRP [median (IQT)] 62 (22.4–129) 200 (90.7–317) 0.03 74 (20.4–144) 97.4 (44.1–299.5) 0.01
Table 4. Inflammatory Response According to Bacteremic Infection




(n = 18) p (n = 51)
No bacteremia
(n = 18) Bacteremia p
IL-6 [median (IQT)] 66 (28.7–199) 202 (61.3–688) 0.03 50.5 (24.8–111.5) 46.2 (25.3–144.6) 0.93
IL-10 [median (IQT)] 1.5 (0–3.3) 12.5 (1.4–21.7) 0.003 1.9 (0–5.5) 4.0 (0.6–12.7) 0.13
Procalcitonin [median (IQT)] 0.3 (0.1–0.9) 3 (0.9–8.8) <0.001 0.2 (0.1–0.9) 2 (0.5–3.9) <0.001
CRP [median (IQT)] 137 (75.3–280) 183 (49.6–340) 0.08 84 (38.4–219) 92 (52–296.5) 0.39
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PA infection and to evaluate their associations with the
clinical severity of infections, outcome, and the pattern of
antimicrobial susceptibility of the different strains.
Systemic cytokine activation was the rule, with predom-
inance of an initial hyperinflammatory phase; the scale of
this phase may be conditioned, by many factors including
pathogen virulence, bacterial load and host factors.29 In line
with previous reports13,14 we found a clear, overall rela-
tionship between the intensity of the inflammatory response,
shown by very high levels of cytokines and biomarkers, and
the severity of the initial clinical presentation. The inflam-
matory response was mainly evident at admission, but some
traces remained 48 hr later. This response was observed
when patients’ severity was classified according to the
SOFA score, but particularly in the cases with bacteremia,
who presented the highest levels. These findings corroborate
previous reports that patients with respiratory tract infec-
tions may show lower levels of cytokines in plasma, due to a
possible compartmentalized immunological response inside
the lung.30
Among the cytokines and biomarkers used in this study,
IL-6 and PCT were the most significant indicators of the
inflammatory response. Compared with PCT, the sensitivity
of CRP was significantly lower. On the other hand, previous
reports have indicated that PCT may be a good marker of
systemic inflammation and severe forms of sepsis,12 but not
for local infections,31 such as pneumonia; therefore, these
findings may suggest that a local bacterial infection does not
induce significant amounts of PCT.
High levels of proinflammatory cytokines have been
correlated with the severity of systemic inflammation and
impaired outcome,32,33 but the authors of previous studies
have emphasized the lack of specificity and note that peak
levels may change rapidly without clinical correlation.
Higher mortality has also been observed in patients with
increasing or persistently high PCT concentrations, although
a recent study showed that single PCT values were not
predictive for patients’ results.12 We found higher levels of
inflammatory cytokines and biomarkers in nonsurvivors in
the early mortality group, but this correlation was quite
weak in comparison with the findings of cytokine levels and
severity of infection. In fact, PCT was the only biomarker of
those studied that showed significant association with early
mortality. No significant association was found with overall
mortality. All these results show that a variety of factors
may condition the outcome of these infections and they do
not receive sufficient consideration when only data of blood
inflammatory markers are evaluated.
Curiously, the analysis of inflammatory markers accord-
ing to the antimicrobial susceptibility of the strains involved
revealed significantly higher values in patients with XDR
PA infections. In fact, a higher score of acute illness at
infection onset and a more severe initial clinical presenta-
tion were observed in this group of XDR PA infection ep-
isodes, which may explain this correlation better than the
antimicrobial pattern of resistance by itself. Thus, bacter-
emic infections were particularly frequent in the XDR PA
group, and the levels of markers in these bacteremic patients
were especially high.
In fact, we conducted a subanalysis including only bac-
teremic infections and no significant differences in the
molecular inflammatory response were observed when com-
paring PA phenotypes. Moreover, levels of biomarkers were
higher in bacteremic infections caused by non-MDR PA than
in those caused by MDR non-XDR and XDR PA strains
(Table 2), although no significance differences were ob-
served. Respiratory tract infections were also less frequent in
the XDR PA group (53%) than in the other two groups (non-
MDR PA: 72,5% and MDR non-XDR group: 83%); as noted
above, low levels of cytokines in plasma may be due to a
compartmentalized inflammatory response in the lung.30 In
addition, there are several factors linked to XDR profile that
could have an impact on the inflammatory response. In fact,
XDR profiles are linked to defined high-risk clones,34 and
these clones are associated with certain biological markers
that could well play a role in the inflammatory response.35
Also, XDR high-risk clones show defined type III secretion
system genotypes, which could certainly have an impact in
the inflammatory response.2 Thus, if the association of high
marker levels and the XDR PA group is due to clinical factors
and not only to microbiological factors, this may also account
for the absence in our study of a stronger correlation between
marker levels and outcome. We observed a tendency toward
higher early mortality in the non-MDR PA group and in fact,
in previous work we found early mortality to be lower in
patients with XDR PA bacteremia than in patients with non-
MDR PA bacteremia.1
Our study has several limitations. The first and major
limitation is the small number of infections recruited, es-
pecially with respect to the analysis of the association be-
tween the results of biomarkers and the resistance profile of
PA. Calculations to estimate power and sample size, based
Table 5. Inflammatory Response and Outcome
Early mortality




(n = 18) p (n = 51)
Survivors
(n = 18) Nonsurvivors p
IL-6 [median (IQT)] 81 (33.5–281) 120 (44.8–507) 0.44 45 (23.3–95.3) 154 (45.3–483) 0.07
IL-10 [median (IQT)] 1.7 (0–5.7) 7.2 (0.6–16.1) 0.21 1.9 (0–5.4) 9.4 (0.2–38.3) 0.11
Procalcitonin [median (IQT)] 0.4 (0.1–1.6) 2 (0.4–5.7) 0.050 0.3 (0.1–1.2) 2.1 (0.3–3.1) 0.06
CRP [median (IQT)] 137 (66.2–285) 262 (63.2–338) 0.41 89 (36.4–230) 131 (46.5–339) 0.45
Overall mortality
IL-6 [median (IQT)] 81 (34.5–281) 120 (27.3–441) 0.58 45 (21.1–95.3) 104 (34.3–278) 0.09
IL-10 [median (IQT)] 1.7 (0–5.7) 2.1 (0–16) 0.50 1.9 (0–5.4) 6.3 (0.1–17.6) 0.16
Procalcitonin [median (IQT)] 0.4 (0.1–1.6) 0.8 (0.3–4.9) 0.12 0.3 (0.1–1.2) 1.2 (0.2–2.4) 0.13
CRP [median (IQT)] 125 (66.2–285) 259 (63.2–328) 0.38 89 (36.4–239) 88 (46.3–276) 0.77
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on the epidemiological data of our hospital, were performed
before the prospective recruitment. However, during the
period of the study the epidemiology of PA infection
changed in our center and we observed less episodes of
infection than expected. Sufficient data for statistical anal-
ysis might have added statistical power and increased the
reliability of the clinical interpretation of the results. Sec-
ond, our work is a descriptive study of the inflammatory
response of patients with PA infection and controls were not
included. The use of ICU patients as controls would have
improved our study. Third, we measured circulating levels
of biomarkers at infection onset and 48 hr afterward, and
this may have limited our ability to explore whether more
time-sensitive patterns existed. Fourth, as the patients in-
cluded in our study were critical patients, some of them
were under corticosteroid or appropriate antibiotic treatment
at the time of the infection onset; a situation that may have
altered their cytokine levels.6,29 In addition, other treatments
and other patient conditions such as age or comorbidities
may also have interfered with the results. Finally, extrapo-
lating our findings in PA infections to other types of in-
fection may be risky, because certain studies have shown
PCT levels, to be significantly higher in the Gram-negative
rod group than in the Gram-positive cocci.36
In conclusion, our study contributes toward a better un-
derstanding of the dynamics of biomarkers’ inflammatory
response in PA infections in ICU patients. A clear association
between the intensity of molecular response and the severity
of initial clinical presentation was observed. However, it was
not clear whether a greater response of inflammatory bio-
markers involves a worse prognosis. Inflammatory response
was considerably higher in patients with bacteremia than in
those with respiratory tract infections. Regarding the anti-
microbial susceptibility of PA strains, no differences were
documented in mortality between XDR and non-MDR PA.
XDR PA infection presented higher values of inflammatory
markers, but a greater number of bloodstream infections in
this group may explain these results; thus should be inter-
preted carefully. Further investigation is needed to elucidate
the clinical implications of these findings.
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